SimBioSys
About SimBioSys
SimBioSys is a pioneering TechBio company dedicated to revolutionizing cancer care through the integration of artificial intelligence (AI) and spatial biophysics. The company develops a sophisticated medical platform that leverages computational oncology to enhance decision-making and improve the patient experience throughout the cancer journey. Their core offering involves transforming comprehensive datasets collected during diagnosis into personalized, virtual 3D tumor models through advanced computational scenario analysis. This innovative approach provides physicians with a deeper, more informed understanding of a patient’s disease, enabling truly individualized treatment strategies.
At the heart of SimBioSys’s technology is TumorScope, a simulation engine that utilizes standard-of-care diagnostic data, such as imaging and pathology, to create spatially resolved virtual replicas of individual tumors and their microenvironment. These mechanistic models incorporate key hallmarks of cancer, including drug sensitivity, metabolism, and mechanical forces, to generate precise and comprehensive predictions of therapy response. This capability also offers crucial insights into mechanisms of resistance, empowering clinicians and patients to computationally assess all available options. Their product portfolio includes TumorSight™ Viz, an FDA-cleared platform for breast cancer surgical visualization and analysis, and the in-development TumorSight™ Risk solution, further expanding their impact on precision oncology and drug development.
Focus Areas
Business Intelligence
| Key Investors | Calculus Venture Capital, Xcellerant Ventures, National Cancer Institute I-Corps, AV8 Ventures, Genoa Ventures, Northpond Ventures, Heritage Medical Group, Mayo Clinic |
| Partnerships | Ricoh 3D for Healthcare, NVIDIA, Mayo Clinic, 20 leading cancer institutions |
| Technology | TumorSight™ Viz, TumorSight™ Risk, TumorScope; combines AI and spatial biophysics, 3D visualization, cloud-based, utilizes NVIDIA A100 Tensor Core GPUs, MONAI and NVIDIA CUDA-X™ libraries |
| FDA Clearances | 3 cleared products (estimated) |
What Physicians Need to Know
For physicians, SimBioSys's TumorSightu2122 Viz offers a transformative tool for preoperative planning in breast cancer, providing clear, interactive 3D visualizations that enhance understanding of tumor spatial relationships and can optimize surgical strategy, potentially expanding breast-conserving options. Utilize these detailed 3D models for patient consultations to improve patient comprehension of their disease and treatment plans, fostering shared decision-making. Keep an eye on their upcoming TumorSightu2122 Risk solution, which promises faster, AI-powered recurrence risk assessments to inform post-surgical treatment decisions. This technology complements existing diagnostic data (MRI, pathology) and aims to standardize presurgical imaging for more consistent and precise outcomes.
The TumorSightu2122 platform is cloud-based, designed for seamless integration into clinical workflows. TumorSightu2122 Viz specifically integrates with hospital PACS systems to streamline planning and coordination. SimBioSys actively engages in strategic collaborations, such as with Mayo Clinic, for the development and validation of their digital precision medicine solutions, and has a strategic alliance with Ricoh 3D for Healthcare to expand access to TumorSightu2122 Viz.
What the Web Says
SimBioSys is a TechBio company that leverages AI and spatial biophysics to redefine precision medicine, particularly in cancer treatment. Their flagship product, TumorSight Viz, is an FDA-cleared tool that transforms 2D DCE-MRIs into interactive 3D models to aid breast cancer surgeons in preoperative planning and patient consultations. The company has received positive feedback from medical professionals regarding the clarity and control it brings to surgical decision-making and its ability to help patients visualize their care. While there are other companies with similar names (SymbioSys Solutions, Symbiosis Finance, Symbiosis Skincare, SimBionic, Simbi, Symbe, Symbios Medical Services, Symbiosys Technologies, Symbiosis Skills & Professional University, Symphony Software), this review focuses on SimBioSys, the healthcare technology company.
Overall: PositiveStrengths
- TumorSight Viz aids in surgical planning for breast cancer by providing 3D visualization and analysis of tumors.
- The technology helps surgeons make more informed decisions about margins, incisions, and reconstruction.
- It assists patients in understanding their treatment trajectory, fostering trust and confidence.
- AI performance in tumor measurement is comparable to expert radiologists.
- The tool provides same-day insights and automates image transfer, improving efficiency.
- SimBioSys collaborates with institutions like Mayo Clinic to advance its platform.
Limitations
- No specific cons for SimBioSys's product or employer reviews were found on the searched platforms (G2, Glassdoor, Capterra, Reddit).
- Some companies with similar names (Symbiosis Skincare) have received negative reviews regarding product legitimacy and inflated pricing.
Based on reviews from: G2, Google Search, Indeed.com, Medical Product Outsourcing, PR Newswire, Trustpilot, TrustRadius
Last updated: 2026-07-19
Videos
News, demos, and interviews about SimBioSys.
Videos load interactively. If none appear, search YouTube for SimBioSys →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded SimBioSys.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]